Brii Biosciences Limited

Equities

2137

KYG1645A1094

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
0.91 HKD -2.15% Intraday chart for Brii Biosciences Limited -8.08% -60.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences MT
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI MT
Transcript : Brii Biosciences Limited - Special Call
Brii Biosciences Hires Chief Scientific Officer MT
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer CI
Brii Biosciences Presents Hepatitis B Treatment Data at US Liver Disease Conference MT
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023 CI
Transcript : Brii Biosciences Limited - Special Call
Brii Biosciences’ Study Into Therapeutic Vaccine for Chronic Hepatitis B Patients Shows Safety, Tolerability MT
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B CI
Brii Biosciences Limited Announces Data from Interim Analysis of A Randomized, Placebo-Controlled and Double-Blinded Phase 2 Study of Brii-179 CI
Transcript : Brii Biosciences Limited - Special Call
Transcript : Brii Biosciences Limited, H1 2023 Earnings Call, Aug 22, 2023
Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shionogi Inc. completed the acquisition of Qpex Biopharma, Inc. from Brii Biosciences Limited and Others. CI
Brii Biosciences Collaborates with VBI Vaccines for Hepatitis B Project MT
Transcript : Brii Biosciences Limited - Special Call
Brii Biosciences Limited Announces Executive Changes CI
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties CI
VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited CI
Vir Biotechnology, VBI Vaccines Release Data Supporting Brii Biosciences Medical Assets in Treating Hepatitis B MT
Brii Biosciences Partners Present Results of Anti-Hepatitis-B Drugs at Liver Congress MT
Brii Biosciences to Acquire Development, Commercialization Rights on Bacterial Drug in Greater China; Shares Up 4% MT
Chart Brii Biosciences Limited
More charts
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Company's products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8403 CNY
Average target price
4.303 CNY
Spread / Average Target
+412.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Brii Biosciences Limited - Hong Kong S.E.
  4. News Brii Biosciences Limited
  5. Brii Biosciences : Seeks Emergency Use Authorization in US for COVID-19 Combination Therapy; Shares Jump 3%